MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$269K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of short-term investm...
Accrued liabilities
Stock-based compensation includi...
Others
Negative Cash Flow Breakdown
Accounts receivable
Change in fair value of 2023 com...
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net (loss) income, as reported
-1,504
-23,040
-19,881
-31,537
Accretion of discount on investments
72
419
444
710
Non cash lease expense
473
509
492
478
Change in fair value of 2023 common warrants
-2,976
-3,395
-1,213
4,205
Depreciation expense
255
346
257
220
Stock-based compensation including espp
1,364
1,314
1,458
1,467
Accounts payable
-1,208
3,657
-669
752
Accrued liabilities
6,707
-1,537
-79
1,400
Operating lease liabilities
-831
-834
-817
-796
Other liabilities
0
-47
-
-
Deferred revenue
0
-
-168
-411
Accounts receivable
27,778
-
-
-
Other assets
-620
-318
681
-587
Net cash and cash equivalents used in operating activities
-24,950
-23,128
-21,745
-24,345
Maturities of short-term investments
25,000
35,000
37,500
70,000
Purchase of short-term investments
0
-
39,429
22,124
Purchases of property and equipment
-1
-69
-92
-193
Net cash and cash equivalents provided by (used in) investing activities
24,999
34,931
-2,021
47,683
Proceeds from issuance of common stock, common warrants and pre-funded warrants in connection with 2025 pipe offering, net of costs
0
-
2
-43
Payments on finance lease
16
62
3
10
Proceeds from the espp purchase
236
-
124
0
Net cash and cash equivalents provided by financing activities
220
-62
123
-53
Net increase (decrease) in cash, cash equivalents, and restricted cash
269
11,741
-23,643
23,285
Cash, cash equivalents, and restricted cash, beginning of period
30,154
18,413
42,056
37,107
Cash, cash equivalents, and restricted cash, end of period
30,423
30,154
18,413
42,056
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of short-term
investments
$25,000K
(25.00%↑ Y/Y)
Proceeds from the espp
purchase
$236K
(31.11%↑ Y/Y)
Net cash and cash
equivalents provided by...
$24,999K
(129.94%↑ Y/Y)
Net cash and cash
equivalents provided by...
$220K
(-99.78%↓ Y/Y)
Canceled cashflow
$1K
Canceled cashflow
$16K
Net increase
(decrease) in cash, cash...
$269K
(101.47%↑ Y/Y)
Canceled cashflow
$24,950K
Purchases of property and
equipment
-$1K
(99.34%↑ Y/Y)
Accrued liabilities
$6,707K
(300.09%↑ Y/Y)
Stock-based compensation
including espp
$1,364K
(-35.63%↓ Y/Y)
Other assets
-$620K
(-226.32%↓ Y/Y)
Non cash lease
expense
$473K
(-47.73%↓ Y/Y)
Depreciation expense
$255K
(-43.71%↓ Y/Y)
Payments on finance lease
$16K
(1500.00%↑ Y/Y)
Net cash and cash
equivalents used in...
-$24,950K
(31.48%↑ Y/Y)
Canceled cashflow
$9,419K
Accounts receivable
$27,778K
Change in fair value of
2023 common warrants
-$2,976K
(95.29%↑ Y/Y)
Net (loss) income,
as reported
-$1,504K
(-105.52%↓ Y/Y)
Accounts payable
-$1,208K
(-190.96%↓ Y/Y)
Operating lease
liabilities
-$831K
(44.56%↑ Y/Y)
Accretion of discount on
investments
$72K
(-93.04%↓ Y/Y)
Buy us a coffee
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. (ALGS)